Status:
COMPLETED
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
Lead Sponsor:
Sanofi
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this retrospective medical record review is to describe the real-world clinical effectiveness of dupilumab with patients in the United Kingdom with severe asthma.
Detailed Description
Participants initiating treatment with dupilumab in the UK between 5th July 2019 and 12th August 2021 will be included in the study record review, permitting participation in research and if medical r...
Eligibility Criteria
Inclusion
- • Adult participants (aged ≥18 years at index) with severe asthma, initiated with dupilumab treatment (≥1 dose) between 07/05/2019 (EU licence) and 08/12/2021 • Participants with ≥1 routine asthma clinic visit recorded within 6 months prior to or on the date of dupilumab initiation and ≥1 routine asthma clinic visit recorded between 9 and 16 months post-dupilumab initiation
Exclusion
- • Participants known to have opted out of participation in research • Participants whose medical records are not available for review The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Key Trial Info
Start Date :
April 19 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 15 2024
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06064526
Start Date
April 19 2023
End Date
October 15 2024
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis, France
Chilly-Mazarin, France, 91380